18:36 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA GI panel backs Pfizer's Xeljanz for ulcerative colitis

FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously in favor of approving twice-daily 10 mg Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The panel also voted 8-7...
22:42 , Mar 8, 2018 |  BC Extra  |  Company News

FDA GI panel backs Xeljanz for UC

FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously in favor of approving twice-daily 10 mg Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The panel also voted 8-7...
08:17 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

FDA panel to discuss Pfizer's Xeljanz for UC

FDA's Gastrointestinal Drugs Advisory Committee will meet on March 8 to discuss an sNDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib tablets to treat adults with moderate to severe active ulcerative colitis. In December, FDA delayed...
21:34 , Jan 19, 2018 |  BC Extra  |  Company News

FDA panel to discuss Pfizer's Xeljanz in UC

FDA's Gastrointestinal Drugs Advisory Committee will meet on March 8 to discuss an sNDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib tablets to treat adults with moderate to severe active ulcerative colitis. In December, FDA...
22:08 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Nimble move

Celgene Corp.’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to two...
00:23 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

FDA to discuss Xeljanz sNDAs in psoriatic arthritis, accepts UC sNDA

FDA’s Arthritis Advisory Committee will meet on Aug. 3 to discuss sNDAs from Pfizer Inc. (NYSE:PFE) for Xeljanz (Jaquinus) tofacitinib and Xeljanz XR extended release to treat adults with active psoriatic arthritis. Pfizer...
21:19 , Apr 25, 2017 |  BC Extra  |  Financial News

Sienna's series B round brings in $40M

Dermatology company Sienna Biopharmaceuticals Inc. (Westlake Village, Calif.) raised $40 million in a series B round led by Arch Venture Partners and Venvest Capital. Also participating were Partner Fund Management, Altitude Life Science Ventures, former...
03:39 , Apr 22, 2017 |  BioCentury  |  Product Development

Playing JAKs

A desire to improve upon marketed autoimmune drug Xeljanz tofacitinib, coupled with interesting biological findings, led Pfizer Inc. to develop a portfolio of selective Janus kinase inhibitors that are taking the target into new disease...
13:01 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Xeljanz regulatory update

China’s FDA approved Xeljanz tofacitinib from Pfizer to treat moderately to severely active rheumatoid arthritis (RA) in adults who have responded inadequately to or are intolerant to methotrexate. The oral pan-Janus kinase (JAK) inhibitor is...
17:06 , Mar 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Chikungunya virus Mouse studies suggest Gilenya fingolimod, Orencia abatacept and Xeljanz tofacitinib could help treat Chikungunya infection. Testing of a total of 11 drugs in mouse models of Chikungunya infection by two independent groups identified...